In the rapidly evolving healthcare landscape of 2026, India has solidified its position as a global pharmacy and a burgeoning hub for medical technology. Central to this growth is a robust regulatory framework managed by the Central Drugs Standard Control Organization (CDSCO). For any business aiming to manufacture, import, or distribute pharmaceutical products and medical equipment in India, obtaining a CDSCO Registration is not just a legal formality—it is a mandatory gateway to market access.
Navigating the complexities of the Medical Devices Rules (MDR) 2017 and its subsequent 2024–2026 amendments requires precision. At Exim Advisory, we understand that regulatory delays can cost lives and revenue. This comprehensive guide breaks down the current framework for CDSCO Registration for Medical Devices and drugs, ensuring your business stays compliant with the latest Indian standards.
Understanding the Role of CDSCO in 2026
The CDSCO, functioning under the Directorate General of Health Services (MoHFW), acts as the National Regulatory Authority (NRA). While State Licensing Authorities (SLA) manage the sale and manufacture of certain categories, the Central Licensing Authority (CLA) maintains absolute control over:
- Approval of “New Drugs” and Investigational New Drugs (IND).
- Granting of CDSCO License for the import of drugs and medical devices.
- Regulation of high-risk medical devices (Class C and Class D).
- Coordination of clinical trials and international regulatory standards.
As of late 2025, the transition from voluntary to mandatory licensing for all medical devices—including non-notified categories—has been completed. This means every diagnostic tool, implant, and even software-as-a-medical-device (SaMD) now requires a formal CDSCO Registration.
Risk-Based Classification: The Foundation of Approval
The first step in any CDSCO Registration journey is identifying the risk category of your product. India follows a four-tier classification system based on the severity of risk to the patient and the user:
- Class A (Low Risk): Includes products like surgical bandages, tongue depressors, and non-sterile thermometers. These often follow a simplified “Self-Declaration” route but still require registration on the SUGAM portal.
- Class B (Low to Moderate Risk): Items such as hypodermic needles, blood pressure monitors, and dental fillings.
- Class C (Moderate to High Risk): Complex equipment like ventilators, bone fixators, and MRI machines.
- Class D (High Risk): Life-sustaining or invasive devices like heart valves, pacemakers, and neurological catheters.
The Step-by-Step Framework for CDSCO Registration
The approval process is now entirely digital, conducted through the SUGAM online portal. Here is the framework followed by a professional CDSCO License Consultant to ensure a seamless approval:
Step 1: Appointment of an Indian Authorized Agent (IAA)
For foreign manufacturers, the law prohibits direct application. You must appoint an Indian Authorized Agent (IAA). This agent acts as the legal representative in India, holding the power of attorney (PoA) and ensuring post-market surveillance compliance. Exim Advisory often serves this critical role for international MedTech firms entering the Indian market.
Step 2: SUGAM Portal Registration
The applicant must create a corporate account on the SUGAM portal. This involves uploading:
- Company PAN and Address Proof.
- Proof of the authorized signatory (Director/Proprietor).
- A valid manufacturing or wholesale license (for domestic entities).
Step 3: Documentation and Technical Dossier Preparation
This is the most critical stage. The CDSCO requires a detailed “Technical Dossier” which includes:
- Plant Master File (PMF): Detailing the manufacturing site’s infrastructure, personnel, and quality control systems.
- Device Master File (DMF): Covering product specifications, intended use, design validation, and biocompatibility studies.
- Free Sale Certificate (FSC): Proof that the device is legally sold in its country of origin.
- ISO 13485 Certification: Ensuring a globally recognized Quality Management System (QMS).
Step 4: Application Submission and Fee Payment
Depending on the intent (Import vs. Manufacture), specific forms are filled:
- Form MD-14: For the import of medical devices.
- Form MD-3/MD-7: For manufacturing licenses (for Class A and B) or loan licenses.
- Form MD-5/MD-9: Actual licenses issued after successful review.
Fees in 2026 are tiered based on the number of manufacturing sites and distinct product categories.
Step 5: Technical Review and Query Management
Once submitted, the CDSCO officers conduct a rigorous technical evaluation. If discrepancies are found, they raise “queries” on the SUGAM dashboard. A CDSCO License Consultant is vital here to provide scientifically backed responses within the stipulated 30-day window to prevent application rejection.
Step 6: Audit and Inspection
For domestic manufacturing, an on-site audit is conducted.
- For Class A and B, registered “Notified Bodies” perform the audit.
- For Class C and D, a joint inspection team from the CDSCO and State authorities is mandated.
Step 7: Grant of License
Upon satisfaction of the CLA, the CDSCO License is issued. Under the recent 2025 amendments, many licenses now enjoy “Perpetual Validity,” provided the retention fees are paid every five years and compliance is maintained.
Recent Regulatory Updates (2025-2026)
Staying updated is non-negotiable in this sector. Recent shifts include:
- Software Regulation: CDSCO has issued strict guidelines for Software as a Medical Device (SaMD), requiring AI-based diagnostic tools to undergo the same rigorous validation as physical hardware.
- Neutral Code for Exports: To boost “Make in India,” manufacturers can now auto-generate “Neutral Codes” via the portal to facilitate exports without revealing sensitive manufacturer data on labels for specific global buyers.
- Stricter Post-Market Surveillance (PMS): License holders must now participate actively in the Materiovigilance Programme of India (MvPI), reporting any adverse events within 15 days.
Why Partner with Exim Advisory?
The road to CDSCO Registration is riddled with technical nuances and changing timelines. A single error in the Device Master File can lead to a six-month delay in product launch.
As a leading CDSCO License Consultant, Exim Advisory provides end-to-end support:
- Strategic Classification: We ensure your device isn’t over-classified, saving you unnecessary fees and audit hurdles.
- Dossier Management: Our experts compile your PMF and DMF to meet the exacting standards of Indian regulators.
- Liaisoning: We handle all communications with the CDSCO headquarters at FDA Bhawan, New Delhi.
- Compliance Monitoring: Beyond the license, we help you manage retention fees and post-market safety reporting.
Essential Documentation Checklist
Before starting your application, ensure you have the following ready:
| Document Type | Requirement Detail |
| Legal Documents | Power of Attorney, Constitution of Firm, Copy of Licenses. |
| Quality Docs | ISO 13485 Certificate, Full Quality Assurance Certificate. |
| Technical Docs | Device Description, Materials used, Shelf-life studies, Sterilization details. |
| Safety Data | Clinical Investigation Reports (for high-risk), Biocompatibility data. |
| Labeling | Draft labels as per Indian Medical Device Rules (Rule 44). |
Conclusion
The Indian medical market offers unparalleled opportunities, but the gatekeeper—the CDSCO—demands absolute compliance with quality and safety standards. Obtaining a CDSCO Registration for Medical Devices or drugs is a testament to a company’s commitment to Indian patient safety. Whether you are a local startup or a global giant, the digital-first approach of the SUGAM portal has made the process more transparent, yet more data-intensive than ever before.
Don’t let regulatory complexity stall your innovation. Let Exim Advisory navigate the framework for you, ensuring your CDSCO License is obtained efficiently and maintained perpetually.
